Net profit of Alivus Life Sciences rose 9.71% to Rs 150.26 crore in the quarter ended December 2025 as against Rs 136.96 crore during the previous quarter ended December 2024. Sales rose 4.84% to Rs 672.89 crore in the quarter ended December 2025 as against Rs 641.84 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales672.89641.84 5 OPM %34.3729.65 - PBDT243.71200.31 22 PBT224.05185.15 21 NP150.26136.96 10 Powered by Capital Market - Live News

Alivus Life Sciences has allotted 55,000 equity shares under ESOS on 21 January 2026. With this allotment, the paid up equity share capital has increased to 12,27,36,348 equity shares of Rs. 2 each aggregating to Rs. 24,54,72,696/-. Powered by Capital Market - Live News

Alivus Life Sciences will hold a meeting of the Board of Directors of the Company on 22 January 2026.Powered by Capital Market - Live News

Net profit of Alivus Life Sciences rose 36.41% to Rs 130.03 crore in the quarter ended September 2025 as against Rs 95.32 crore during the previous quarter ended September 2024. Sales rose 16.00% to Rs 587.98 crore in the quarter ended September 2025 as against Rs 506.88 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales587.98506.88 16 OPM %30.4726.51 - PBDT192.58142.55 35 PBT174.14127.46 37 NP130.0395.32 36 Powered by Capital Market - Live News

Alivus Life Sciences will hold a meeting of the Board of Directors of the Company on 6 November 2025.Powered by Capital Market - Live News